MDT · Medtronic plc
$89.97
-2.05 (-2.23%)
At close · Aug 27
Market Cap
$117.57B
Shares
1.28B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$89.97
Open$91.50
Day$89.96–91.61
52W close$73.75–105.35
Avg vol 30d6.9M
Short int14.4M · 1.1% float · 2.3d
Short vol42%
Last earningsJun 3, 2026
DataJan 2020–Aug 2026
Filing10-K · Jun 18
Up next
Next earnings call
Sep 2, 2026
Est · unconfirmed
· in 1 wks
FQ2-27 quarter ends
~Oct 24, 2026
Est
filed Jun 18, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Low
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
+6%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
51%
mid-range
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−1%
trailing
YTD return
−6%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $85 › 200d $90 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +168 funds added
Insider flow
Distributing
Net -$337.0K over 90 days · 100% sells
Short interest
Falling
1.12% of float · ▼ -20.8% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2,108 holders — mid 3-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
57%
contracting
EPS growth
+3%
Y/Y
Free cash flow
$5.4B
Valuation
P/E 24.6
below peers
Buyback
$1.2B
remaining
Balance sheet
$22.0B
net debt
Quant / Vol
risk profile
Volatility
23%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jun 3, 2026
Organic revenue growth
· FY27
Non-GAAP
Initiated
6.75% – 7.25%
Prior guidance
period ended
· from the Earnings Call filed Apr 30, 2026
Organic revenue growth
· the first quarter
11.5% – 12%
Tariff impact to COGS
· fiscal year 27 first quarter
$75M
Guided vs delivered
· last 2 settled
EPS
the third quarter
guided $1.25 – $1.27
$0.99
Miss −21.4%
EPS
first quarter
guided $1.10 – $1.12
$0.59
Miss −46.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
51%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $85 › 200d $90 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +168 funds added
Insider flow
Distributing
Net -$337.0K over 90 days · 100% sells
Short interest
Falling
1.12% of float · ▼ -20.8% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2,108 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $74
Now $90 · 51%
Range high $105
vs 200-day avg +0%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cardiac Ablation Solutions revenue growth (global) | 78% | Q4 FY26 | — |
| Cardiac Ablation Solutions revenue growth (U.S.) | 124% | Q4 FY26 | — |
| Free cash flow non-GAAP | $5.43B | FY26 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 7.33B
-1.9B Additions to property, plant, and equipment
= Free Cash Flow 5.43B
|
|||
| Free cash flow conversion from non-GAAP net earnings non-GAAP | 76% | FY26 | — |
| FY26 organic revenue growth non-GAAP | 5.8% | FY26 | — |
| Non-GAAP operating margin non-GAAP | 24.4% | FY26 | — |
| Non-GAAP operating profit non-GAAP | $8.86B | FY26 | — |
| Organic revenue growth non-GAAP | 5.8% | FY26 | — |
| Q4 FY26 organic revenue growth non-GAAP | 6.6% | Q4 FY26 | — |
| Cardiac Ablation Solutions revenue | 80% | Q3 FY2026 | — |
| Cardiac Ablation Solutions revenue (U.S.) | 137% | Q3 FY2026 | — |
| Cardiovascular Portfolio revenue growth (organic) non-GAAP | 10.6% | Q3 FY2026 | — |
| Diabetes revenue growth (organic) non-GAAP | 8.3% | Q3 FY2026 | — |
| Medical Surgical Portfolio revenue growth (organic) non-GAAP | 2.7% | Q3 FY2026 | — |
| Neuroscience Portfolio revenue growth (organic) non-GAAP | 2.5% | Q3 FY2026 | — |
| Q3 non-GAAP net income non-GAAP | $1.75B | Q3 FY2026 | — |
| Q3 non-GAAP operating margin non-GAAP | 24.1% | Q3 FY2026 | — |
| Q3 non-GAAP operating profit non-GAAP | $2.18B | Q3 FY2026 | — |
| Total revenue growth (organic) non-GAAP | 6% | Q3 FY2026 | — |
| Total revenue growth (reported) | 8.7% | Q3 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDT
this stock
Medtronic plc
|
$117.57B | -6.3% | +8.4% | 24.6 | 1.1% |
|
ABT
Abbott Laboratories
|
$198.74B | -10.9% | +5.7% | 32.0 | 1.2% |
|
SYK
Stryker Corp
|
$126.45B | -8.4% | +11.2% | 34.2 | 1.8% |
|
BSX
Boston Scientific Corp
|
$68.44B | -51.1% | +12.5% | 19.1 | 1.9% |
|
EW
Edwards Lifesciences Corp
|
$51.85B | +5.5% | +11.5% | 51.7 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDT | -2.5% | +5.0% | -1.0% | +5.4% | -6.3% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -3.6% | +1.0% | -15.7% | +2.1% | -19.4% |
Capital returns
Latest dividend
$0.72
/ share · ex Jun 26, 2026
Declared · upcoming
$0.72
/ share · ex Sep 25, 2026
Paid (TTM)
$2.85
/ share · 4 payouts
Dividend yield (TTM, derived)
3.17%
Buyback program
· as of Apr 24, 2026
Authorized
$11.00B
Spent (derived)
$9.80B
Remaining
$1.20B
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.